Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

References

• Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Int Med. 2017;5(3):139–143.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute, Bethesda, MD, based on November 2019 SEER data submission, posted to the SEER website, April 2020. Available from: https://seer.cancer.gov/csr/1975_2017/
   Google Scholar
• Sekeres MA. The epidemiology of myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010;24(2):287–294.
   PubMed Web of Science ®Google Scholar
• Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112(1):45–52.
   PubMed Web of Science ®Google Scholar
• Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109(8):1536–1542.
   PubMed Web of Science ®Google Scholar
• Della Porta MG, Tuechler H, Malcovati L, et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015;29(7):1502–1513.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Stem cell transplant for myelodysplastic syndrome; 2018 [cited 2020 Aug 5]. Available from: https://www.cancer.org/cancer/myelodysplastic-syndrome/treating/stem-cell-transplant.html.
   Google Scholar
• Wang R, Gross CP, Maggiore RJ, et al. Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes. Leuk Res. 2011;35(7):904–908.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011 May 20;29(15):1987–1996.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20;24(24):3895–3903.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–414.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Davidoff AJ, Long JB, et al. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. Br J Haematol. 2016;175(5):829–840.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121–7125.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VIDAZA® (azacitidine): highlights of prescribing information; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050794s032lbl.pdf
   Google Scholar
• Food and Drug Administration. DACOGEN® (decitabine): highlights of prescribing information; 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021790s025lbl.pdf
   Google Scholar
• National Cancer Institute. Overview of the SEER program. [cited 2020 June 6]. Available from: https://seer.cancer.gov/about/factsheets/SEER_Overview.pdf.
   Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV–18.
   Web of Science ®Google Scholar
• Hatoum HT, Lin SJ, Buchner D, et al. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study. Curr Med Res Opin. 2011;27(6):1255–1262.
   PubMed Web of Science ®Google Scholar
• Grinblatt DL, Sekeres MA, Komrokji RS, et al. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015;56(4):887–895.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, Version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108(10):3271–3279.
   PubMed Web of Science ®Google Scholar
• Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110(7):2302–2308.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol. 2011;29(5):516–523.
   PubMed Web of Science ®Google Scholar
• Papageorgiou SG, Kontos CK, Kotsianidis I, et al. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: a retrospective analysis of the Hellenic (Greek) MDS Study Group. Hematol Oncol. 2018;36(4):693–700.
   PubMed Web of Science ®Google Scholar
• Cogle CR, Kurtin SE, Bentley TG, et al. The incidence and health care resource burden of the myelodysplastic syndromes in patients in whom first-line hypomethylating agents fail. Oncologist. 2017;22(4):379–385.
   PubMed Web of Science ®Google Scholar
• Harel S, Cherait A, Berthon C, et al. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure. Leuk Res. 2015;39(5):501–504.
   PubMed Web of Science ®Google Scholar
• Cabrero M, Jabbour E, Ravandi F, et al. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up. Leuk Res. 2015;39(5):520–524.
   PubMed Web of Science ®Google Scholar
• Kim DJ, Lee HS, Moon JH, et al. Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome: a retrospective study from The Korean Society of Hematology AML/MDS Working Party. Oncotarget. 2017;8(45):79414–79424.
   PubMedGoogle Scholar
• Ricco A, Sgherza N, Rossi AR, et al. Long-term outcome of higher-risk MDS patients treated with azacitidine: single centre experience. Blood. 2013;122(21):5220–5220.
   Web of Science ®Google Scholar
• Williams DM. Pancytopenia, aplastic anemia and pure red cell aplasia. In Wintrobe’s clinical hematology. 10th ed. Baltimore (MD): William and Willkins; 1993. p. 1449–1484.
   Google Scholar
• Jalaeikhoo H, Kashfi SMH, Azimzadeh P, et al. Acute myeloid leukemia as the main cause of pancytopenia in Iranian population. Iran J Pathol. 2017;12(3):265–271.
   PubMedGoogle Scholar
• Jha A, Sayami G, Adhikari RC, et al. Bone marrow examination in cases of pancytopenia. JNMA J Nepal Med Assoc. 2008;47(169):12–17.
   PubMed Web of Science ®Google Scholar
• Sharma R, Nalepa G. Evaluation and management of chronic pancytopenia. Pediatr Rev. 2016;37(3):101–111.
   PubMed Web of Science ®Google Scholar
• Das Makheja K, Kumar Maheshwari B, Arain S, et al. The common causes leading to pancytopenia in patients presenting to tertiary care hospital. Pak J Med Sci. 2013;29(5):1108–1111.
   PubMed Web of Science ®Google Scholar
• Giagounidis A. Current treatment algorithm for the management of lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2017;2017(1):453–459.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Sekeres MA, Garcia-Manero G, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016;30(3):649–657.
   PubMed Web of Science ®Google Scholar
• Porwit A, Saft L. The AML-MDS interface-leukemic transformation in myelodysplastic syndromes. J Hematopathol. 2011;4(2):69–79.
   Google Scholar
• Saber W, Horowitz MM. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology Am Soc Hematol Educ Program. 2016;2016(1):478–484.
   PubMed Web of Science ®Google Scholar
• Platzbecker U. Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights. Hematology Am Soc Hematol Educ Program. 2013;2013:522–528.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Linhares Y, Gore SD. Current therapy of myelodysplastic syndromes. Blood Rev. 2013;27(5):243–259.
   PubMed Web of Science ®Google Scholar
• Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239–2252.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Stahl M, Hu X, et al. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood. 2018;131(7):818–821.
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Gore SD. Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation? Expert Rev Hematol. 2013;6(5):539–542.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer. 2010;116(16):3830–3834.
   PubMed Web of Science ®Google Scholar